Abstract
Mycobacterium tuberculosis meningitis is the most lethal extrapulmonary form of active tuberculosis with high prevalence in developing countries, which constitutes a public health problem. The extrapulmonary presentation that compromise the nervous system include meningeal tuberculosis, tuberculous granuloma, tuberculosis abscess and radiculomyelitis. A nonspecific clinical presentation, the lack of rapid tests with high sensitivity and specificity, the high cost and poor affordability of testing in many countries make the diagnosis more complicated. The diagnosis is based on microbiological, molecular, and host response based testing. Microbiological diagnosis is based on Ziehl - Neelsen staining and culture, the latter long considered the gold standard diagnostic test. Molecular diagnosis is more accurate using nucleic acid amplification tests, the chain reaction of polymerase, the GeneXpert MTB / RIF test, and the Xpert MTB / RIF Ultra test. Given the absence of a rapid test, there are scales that help guide the patient's diagnosis, within which the Thwaites Scale and the Marais Scale deserve to be mentioned. The treatment of tuberculosis of susceptible strains includes a structured regimen with isoniazid, rifampicin, pyrazinamide and ethambutol, however, antimicrobial resistance is currently a problem for which the treatment of multidrug-resistant tuberculosis must be individualized, with a long-term treatment regimen.
References
Chin JH. Tuberculous meningitis: Diagnostic and therapeutic challenges. Neurol Clin Pract. 2014;4(3):199-205. doi: 10.1212/CPJ.0000000000000023.
Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol. 2013;12(10):999-1010. doi: 10.1016/S1474-4422(13)70168-6.
Gómez-Ayerbe C, Vivancos MJ, Moreno S. Tuberculosis multirresistente: epidemiología actual, esquemas terapéuticos, nuevos fármacos. Rev Esp Quim. 2016;29(1):35-8.
COVID-19 y tuberculosis: necesitamos solidaridad global [Internet]. Médicos Sin Fronteras. 2020 [citado 2020 Ago. 24]. p. 1. Disponible en: Disponible en: https://www.msf.es/actualidad/covid-19-y-tuberculosis-necesitamos-solidaridad-global
Lindmeier C. Las nuevas recomendaciones de la OMS para prevenir la tuberculosis aspiran a salvar millones de vidas [Internet]. Comunicado de prensa. 2020 [citado 2020 Ago. 24]. p. 1. Disponible en: Disponible en: https://www.who.int/es/news-room/detail/24-03-2020-new-who-recommendations-to-prevent-tuberculosis-aim-to-save-millions-of-lives
Mezochow A, Thakur K, Vinnard C. Tuberculous meningitis in children and adults: new insights for an ancient foe. Curr Neurol Neurosci Rep. 2017;17(11):85. doi: 10.1007/s11910-017-0796-0.
Vargas Restrepo F. Tuberculosis activa en trabajadores de salud en Colombia 2011-2017. Medellín: Universidad de Antioquia; 2019.
Bermúdez Pinzón L. Informe del evento,Tuberculosis. Colombia; 2020.
Bermúdez Pinzón L. Informe de evento, Tuberculosis farmacorresistente. Instituto Nacional de Salud; 2020.
Quintero P, Calderón C, López V, Correa N, Quintero L. Características clínicas y diagnósticas de tuberculosis meníngea en adultos, Bogotá (Colombia). Acta Neurol Colomb. 2015;31(2):150-7.
Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Prim. 2016;2(1):16076. doi: 10.1038/nrdp.2016.76.
Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev. 2008;21(2):243-61. doi: 10.1128/CMR.00042-07.
Wilkinson RJ, Rohlwink U, Misra UK, Van Crevel R, Mai NTH, Dooley KE, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13(10):581-98. doi: 10.1038/nrneurol.2017.120.
Davis AG, Rohlwink U, Proust A, Figaji A, Wilkinson RJ. The Pathogenesis of tuberculous meningitis. J Leukoc Biol. 2019;105(2):267-80. doi: 10.1002/JLB.MR0318-102R.
Leonard JM. Central nervous system tuberculosis. Microbiol Spectr. 2017;5(2):1-10. doi: 10.1128/microbiolspec.TNMI7-0044-2017.
Nguyen L, Pieters J. The Trojan horse: Survival tactics of pathogenic mycobacteria in macrophages. Trends Cell Biol. 2005;15(5):269-76. doi: 10.1016/j.tcb.2005.03.009.
Be NA, Kim KS, Bishai WR, Jain S. Pathogenesis of central nervous system tuberculosis. Curr Mol Med. 2009;9(2):94-9. doi: 10.2174/156652409787581655.
Randall PJ, Hsu NJ, Lang D, Cooper S, Sebesho B, Allie N, et al. Neurons are host cells for Mycobacterium tuberculosis. Infect Immun. 2014;82(5):1880-90. doi: 10.1128/IAI.00474-13.
Peterson PK, Gekker G, Hu S, Sheng WS, Anderson WR, Ulevitch RJ, et al. CD14 receptor-mediated uptake of non-opsonized Mycobacterium tuberculosis by human microglia. Infect Immun. 1995;63(4):1598-602. doi: 10.1128/IAI.63.4.1598-1602.1995.
Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101(2):311-20. doi: 10.1172/JCI1368.
Zunt JR. Tuberculosis of the central nervous system. Continuum (Minneap Minn). 2018;24(5):1422-38. doi: 10.1212/CON.0000000000000648.
Vidal JE, Penalva De Oliveira AC, Bonasser Filho F, Schiavon Nogueira R, Dauar RF, Leite AG, et al. Tuberculous brain abscess in AIDS patients: Report of three cases and literature review. Int J Infect Dis. 2005;9(4):201-7. doi: 10.1016/j.ijid.2004.06.010.
Hernández-Albújar S, Arribas JR, Royo A, González-García JJ, Peña JM, Vázquez JJ. Tuberculous radiculomyelitis complicating tuberculous meningitis: Case report and review. Clin Infect Dis. 2000;30(6):915-21. doi: 10.1086/313821.
Wang YY, Xie BD. Progress on diagnosis of tuberculous meningitis. Methods Mol Biol. 2018;1754:375-86. doi: 10.1007/978-1-4939-7717-8_20.
Thwaites GE, Chau TTH, Farrar JJ. Improving the bacteriological diagnosis of tuberculous meningitis. J Clin Microbiol. 2004;42(1):378-9. doi: 10.1128/jcm.42.1.378-379.2004.
Török ME. Tuberculous meningitis: Advances in diagnosis and treatment. Br Med Bull. 2015;113(1):117-31. doi: 10.1093/bmb/ldv003.
Pormohammad A, Nasiri MJ, McHugh TD, Riahi SM, Bahr NC. A systematic review and meta-analysis of the diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis. J Clin Microbiol. 2019;57(6):633-43. doi: 10.1128/JCM.01113-18.
Pai M, Flores LL, Pai N, Hubbard A, Riley LW CJJ. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2003;3(10):633-43. doi: 10.1016/s1473-3099(03)00772-2.
Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, nearpatient technology. J Clin Microbiol. 2010;48(1):229-37. doi: 10.1128/JCM.01463-09.
Kohli M, Schiller I, Dendukuri N, Dheda K, Cm D, Sg S, et al. Xpert ® MTB / RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review). Cochrane Libr. 2018;(8). doi: 10.1002/14651858.CD012768.pub2.
Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, et al. Diagnostic accuracy of Xpert MTB/ RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis. 2018;18(1):68-75. doi: 10.1016/S1473-3099(17)30474-7.
Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K. The World Health Organization standards for tuberculosis care and management. Eur Respir J. 2018;51(3):16-21. doi: 10.1183/13993003.00098-2018.
Tuon FF, Higashino HR, Lopes MIBF, Litvoc MN, Atomiya AN, Antonangelo L, et al. Adenosine deaminase and tuberculous meningitis A systematic review with meta-analysis. Scand J Infect Dis. 2010;42(3):198-207. doi: 10.3109/00365540903428158.
Thwaites GE, Chau TTH, Stepniewska K, Phu NH, Chuong LV, Sinh DX, et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet. 2002;360(9342):1287-92. doi: 10.1016/s0140-6736(02)11318-3.
Saavedra JS, Urrego S, Toro ME, Uribe CS, García J, Hernández O, et al. Validation of Thwaites Index for diagnosing tuberculous meningitis in a Colombian population. J Neurol Sci. 2016;370:112-8. doi: 10.1016/j.jns.2016.09.007.
Marais S, Thwaites G, Schoeman JF, Tòròk ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803-12. doi: 10.1016/S1473-3099(10)70138-9.
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):853-67. doi: 10.1093/cid/ciw566.
Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4(4):CD002244. doi: 10.1002/14651858.CD002244.pub4.
Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3). doi: 10.1183/13993003.023082016.
Zignol M, Dean AS, Falzon D, Gemert W Van, Wright A, Deun A Van, et al. Special report twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med. 2016;1081-9. doi: 10.1056/NEJMsr1512438.
Pontali E, Raviglione MC, Migliori GB, Akkerman OW, Alffenaar JW, Blanc FX, et al. Regimens to treat multidrug-resistant tuberculosis: Past, present and future perspectives. Eur Respir Rev. 2019;28(152). doi: 10.1183/16000617.0035-2019.
Mase SR, Chorba T. Treatment of drug-resistant tuberculosis. Clin Chest Med. 2019;40(4):775-95. doi: 10.1016/j.ccm.2019.08.002.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.